keyword
MENU ▼
Read by QxMD icon Read
search

ctDNA

keyword
https://www.readbyqxmd.com/read/29218272/blood-based-biomarkers-in-lung-cancer-prognosis-and-treatment-decisions
#1
REVIEW
Meng Xu-Welliver, David P Carbone
Despite recent advances, non-small cell lung cancer (NSCLC) remains a devastating disease with overall poor prognosis. Major contributing factors include obstacles to diagnosing the disease early in its course during the asymptomatic stage as well as diversity and complexity of its biology underlying tumorigenesis and tumor progression. Advances in molecularly targeted therapies which drives the development of personalized cancer care require precise and comprehensive understanding of tumor biology, not only at the time of diagnosis but also during treatment course and surveillance...
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29218268/blood-based-tumor-biomarkers-in-lung-cancer-for-detection-and-treatment
#2
REVIEW
Hirva Mamdani, Shahid Ahmed, Samantha Armstrong, Tony Mok, Shadia I Jalal
The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor biology have made it imperative to obtain tumor samples on several different occasions through the course of patient treatment. While this approach is critical to the delivery of optimal cancer treatment, it is fraught with a number of barriers including the need for invasive procedures with associated complications, access to limited amount of tissue, logistical delays in obtaining the biopsy, high healthcare cost, and in many cases inability to obtain tissue because of technically difficult location of the tumor...
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29216356/improved-egfr-mutation-detection-using-combined-exosomal-rna-and-circulating-tumor-dna-in-nsclc-patient-plasma
#3
A K Krug, D Enderle, C Karlovich, T Priewasser, S Bentink, A Spiel, K Brinkmann, J Emenegger, D G Grimm, E Castellanos-Rizaldos, J W Goldman, L V Sequist, J-C Soria, D R Camidge, S M Gadgeel, H A Wakelee, M Raponi, M Noerholm, J Skog
Background: A major limitation of circulating tumor DNA (ctDNA) for somatic mutation detection has been the low level of ctDNA found in a subset of cancer patients. We investigated whether using a combined isolation of exosomal RNA (exoRNA) and cell-free DNA (cfDNA) could improve blood-based liquid biopsy for EGFR mutation detection in NSCLC patients. Patients and methods: Matched pretreatment tumor and plasma were collected from 84 patients enrolled in TIGER-X (NCT01526928), a Ph1/2 study of rociletinib in mutant EGFR NSCLC patients...
December 5, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29216340/incorporating-blood-based-liquid-biopsy-information-into-cancer-staging-time-for-a-tnmb-system
#4
M Yang, M E Forbes, R L Bitting, S S O'Neill, P-C Chou, U Topaloglu, L D Miller, G A Hawkins, S C Grant, B R DeYoung, W J Petty, K Chen, B C Pasche, W Zhang
Tissue biopsy is the standard diagnostic procedure for cancer. Biopsy may also provide material for genotyping, which can assist in the diagnosis and selection of targeted therapies but may fall short in cases of inadequate sampling, particularly from highly heterogeneous tumors. Traditional tissue biopsy suffers greater limitations in its prognostic capability over the course of disease, most obviously as an invasive procedure with potential complications, but also with respect to probable tumor clonal evolution and metastasis over time from initial biopsy evaluation...
December 5, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29212777/detection-and-monitoring-of-circulating-tumor-dna-in-adrenocortical-carcinoma
#5
Simon Garinet, Juliette Nectoux, Mario Neou, Eric Pasmant, Anne Jouinot, Mathilde Sibony, Lucie Orhant, Juliana Pipoli da Fonseca, Karine Hecale-Perlemoine, Leopoldine Bricaire, Lionel Groussin, Olivier Soubrane, Bertrand Dousset, Rossella Libé, Franck Letourneur, Jerome Bertherat, Guillaume Assié
Adrenocortical carcinomas (ACC) are aggressive tumors with limited prognostic and follow-up biomarkers. Circulating tumor DNA (ctDNA) is an emerging biomarker, now used for several cancer types. This study aimed to reliably detect and quantify ctDNA in ACC patients; to identify parameters impacting detection of ctDNA. A prospective monocentric study conducted in Cochin Hospital and Cochin Institute, Paris, France. Eleven ACC patients were included with either primary tumor or relapse or metastases from 2015 to 2016...
December 6, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29210128/one-pot-synthesis-and-characterization-cdte-zn2-quantum-dots-and-its-molecular-interaction-with-calf-thymus-dna
#6
Cheng-Zhang Yang, Lin-Yi Li, Xiao-Han Wang, Si-Qian Yu, Yan-Jun Hu
Tremendous research efforts have been dedicated to fabricating high-quality Zn-doped CdTe quantum dots (QDs) for any potential biomedical applications. In particular, the correlation of issues regarding how QDs interact with DNA is of greatest importance. Herein, a pH-responsive study of the interactions between CdTe:Zn2+ quantum dots with 4 different sizes and calf thymus DNA (ctDNA) was conducted using multispectroscopic techniques and electrochemical investigation. Fluorescence studies revealed that this interaction process is predominantly a static process and groove binding was the main binding mode for CdTe:Zn2+ QDs to ctDNA...
December 6, 2017: Journal of Molecular Recognition: JMR
https://www.readbyqxmd.com/read/29208774/predicting-relapse-with-circulating-tumor-dna-analysis-in-lung-cancer
#7
COMMENT
Iñaki Comino-Mendez, Nicholas Turner
<b/> Advances in circulating tumor DNA (ctDNA) analysis are revealing new treatment strategies for patients with cancer. Detection of residual disease with ctDNA analysis predicts relapse with high accuracy after treatment for early-stage lung cancer. Cancer Discov; 7(12); 1368-70. ©2017 AACRSee related article by Chaudhuri et al., p. 1394.
December 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29207318/her2-copy-number-of-circulating-tumour-dna-functions-as-a-biomarker-to-predict-and-monitor-trastuzumab-efficacy-in-advanced-gastric-cancer
#8
Haixing Wang, Beifang Li, Zhentao Liu, Jifang Gong, Lin Shao, Jun Ren, Yunyun Niu, Shiping Bo, Zhongwu Li, Yumei Lai, Sijia Lu, Jing Gao, Lin Shen
BACKGROUND: HER2 status is significant to trastuzumab therapy; however, it is difficult to determine HER2 status accurately with few pieces of biopsies from advanced gastric cancer (AGC) due to highly heterogeneity and invasive behaviour, which will be investigated in this study. METHODS: Fifty-six patients with AGC were included in this study. Primary tumour tissues and matched plasmas before medication from 36 patients were retrospectively collected, and the other 20 patients with primary tumour tissues and paired plasmas were prospectively collected...
December 2, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29206995/concordance-of-circulating-tumor-dna-and-matched-metastatic-tissue-biopsy-in-prostate-cancer
#9
Alexander W Wyatt, Matti Annala, Rahul Aggarwal, Kevin Beja, Felix Feng, Jack Youngren, Adam Foye, Paul Lloyd, Matti Nykter, Tomasz M Beer, Joshi J Alumkal, George V Thomas, Robert E Reiter, Matthew B Rettig, Christopher P Evans, Allen C Gao, Kim N Chi, Eric J Small, Martin E Gleave
Background: Real-time knowledge of the somatic genome can influence management of patients with metastatic castration-resistant prostate cancer (mCRPC). While routine metastatic tissue biopsy is challenging in mCRPC, plasma circulating tumor DNA (ctDNA) has emerged as a minimally invasive tool to sample the tumor genome. However, no systematic comparisons of matched "liquid" and "solid" biopsies have been performed that would enable ctDNA profiling to replace the need for direct tissue sampling...
December 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29205637/a-field-guide-for-cancer-diagnostics-using-cell-free-dna-from-principles-to-practice-and-clinical-applications
#10
REVIEW
Anna-Lena Volckmar, Holger Sültmann, Anja Riediger, Thoas Fioretos, Peter Schirmacher, Volker Endris, Albrecht Stenzinger, Steffen Dietz
Recently, many genome-wide profiling studies provided insights into the molecular background of major cancer types. The deeper understanding of the genetic alterations and their functional consequences leveraged the discovery of novel therapeutic opportunities, improving clinical management of cancer patients. While tissue-based molecular patient stratification is the gold standard for precision medicine, it has certain limitations: Tissue biopsies are risky invasive sampling procedures and may not represent the entire tumor due to genetic heterogeneity...
December 5, 2017: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/29199710/incidence-and-characteristics-of-epidermal-growth-factor-receptor-egfr-mutation-in-non-small-cell-lung-cancer-adenocarcinoma-histology-a-report-of-106-patients-from-kolkata
#11
K Chatterjee, A Ray, B Chattopadhyay
CONTEXT: Regional epidemiological data regarding the epidermal growth factor receptor (EGFR) mutation status in non-small-cell lung cancers (NSCLC) is an unmet need from the eastern part of India. AIMS: To report the incidence of EGFR mutation and its correlation with the phenotypical characteristics, in NSCLC patients from Kolkata. SUBJECTS AND METHODS: NSCLC patients, with adenocarcinoma histology, whose tissues had been tested for EGFR mutational status between March 2014 and February 2017, were considered for this study...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29196748/cell-free-dna-kinetics-in-a-pre-clinical-model-of-head-and-neck-cancer
#12
Nidal Muhanna, Marco A Di Grappa, Harley H L Chan, Tahsin Khan, Cheng S Jin, Yangqiao Zheng, Jonathan C Irish, Scott V Bratman
In cancer patients, circulating tumour-derived DNA (ctDNA) levels imperfectly reflect disease burden apparent on medical imaging. Further evaluation of ctDNA levels over time is needed to better understand the correlation with tumour growth and therapeutic response. We describe ctDNA kinetics within an orthotopic, immunocompetent preclinical rabbit model of local-regionally advanced head and neck squamous cell carcinoma (HNSCC). Monitoring primary tumour and metastatic lymph node volume by computed tomography (CT), we observed a correlation between ctDNA levels and tumour burden...
December 1, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29195807/parallel-evaluation-of-circulating-tumor-dna-and-circulating-tumor-cells-in-metastatic-colorectal-cancer
#13
Giovanni Germano, Gianluca Mauri, Giulia Siravegna, Caroline Dive, Jackie Pierce, Federica Di Nicolantonio, Maurizio D'Incalci, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi
BACKGROUND: Tissue biopsy is the gold standard for tumor genotyping, but it is an invasive procedure providing a single snapshot into tumor heterogeneity. Liquid biopsy approaches, encompassing the analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), have been proposed as an alternative, with the potential of providing a comprehensive portrait of the tumor molecular landscape. In metastatic colorectal cancer (mCRC), both CTCs and ctDNA analysis have been investigated, but comparative analyses are limited...
November 1, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29192597/circulating-tumour-dna-analytical-aspects-and-clinical-applications-for-metastatic-melanoma-patients
#14
Guillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, Sandrine Théoleyre, Gaëlle Quéreux, Amir Khammari, Brigitte Dréno, Marc G Denis
The management of metastatic melanoma has evolved since the onset of treatments with BRAF inhibitors. In order to predict which patients are likely to respond to these treatments, the therapeutic strategy is now conditioned by the search for the activating mutations of the BRAF gene. Tumor genotyping is routinely performed from DNA extracted from tissue or cellular specimens from the primary tumor, metastases, or neoplastic effusions. Due to their invasiveness, these specimens are rarely repeated during the management...
December 1, 2017: Annales de Biologie Clinique
https://www.readbyqxmd.com/read/29184672/new-insights-in-non-small-cell-lung-cancer-circulating-tumor-cells-and-cell-free-dna
#15
REVIEW
Elena Duréndez-Sáez, Aitor Azkárate, Marina Meri, Silvia Calabuig-Fariñas, Cristóbal Aguilar-Gallardo, Ana Blasco, Eloisa Jantus-Lewintre, Carlos Camps
Lung cancer is the second most frequent tumor and the leading cause of death by cancer in both men and women. Increasing knowledge about the cancer genome and tumor environment has led to a new setting in which morphological and molecular characterization is needed to treat patients in the most personalized way in order to achieve better outcomes. Since tumor products can be detected in body fluids, the liquid biopsy, particularly, peripheral blood, has emerged as a new source for lung cancer biomarker's analysis...
October 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29184671/urine-test-for-egfr-analysis-in-patients-with-non-small-cell-lung-cancer
#16
REVIEW
Aleksandra Franovic, Victoria M Raymond, Mark G Erlander, Karen L Reckamp
Precision medicine approaches in oncology are reliant on the accurate genomic characterization of tumors. While tissue remains the mainstay specimen for molecular testing, tumor biopsies are riddled with challenges and limitations due to their invasive and site-specific nature. Tumor inaccessibility and intratumoral heterogeneity, in particular, represent significant obstacles to the identification of actionable genetic alterations and hence effective mono- and combination therapy strategies. Proof-of-concept studies indicate that circulating tumor DNA (ctDNA) released from multiple tumor regions and anatomical locations is more reflective of intra- and intertumoral heterogeneity...
October 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29180605/cell-free-dna-and-circulating-tumor-cells-comprehensive-liquid-biopsy-analysis-in-advanced-breast-cancer
#17
Giovanna Rossi, Zhaomei Mu, Alfred Rademaker, Laura Austin, Kimberly S Strickland, Ricardo Lima Barros Costa, Rebecca Nagy, Vittorina Zagonel, Timothy J Taxter, Amir Behdad, Firas H Wehbe, Leonidas C Platanias, William Gradishar, Massimo Cristofanilli
PURPOSE: Liquid biopsy provides a real-time assessment of metastatic breast cancer (MBC). We evaluated the utility of combining circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) to predict prognosis in MBC. EXPERIMENTAL DESIGN: We conducted a retrospective study of 91 patients with locally advanced and MBC. CTCs were enumerated by CellSearch; the plasma-based assay was performed utilizing Guardant360TM and the survival analysis using Kaplan-Meier curves...
November 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29156805/circulating-tumor-dna-shows-variable-clonal-response-of-breast-cancer-during-neoadjuvant-chemotherapy
#18
Ji-Yeon Kim, Donghyun Park, Dae-Soon Son, Seok Jin Nam, Seok Won Kim, Hae Hyun Jung, Yeon Jeong Kim, Gahee Park, Woong-Yang Park, Jeong Eon Lee, Yeon Hee Park
Circulating tumor DNA (ctDNA) correlates with tumor burden and provides early detection of treatment response and tumor genetic alterations in breast cancer (BC). In this study, we aimed to identify genetic alterations during the process of tumor clonal evolution and examine if ctDNA level well indicated clinical response to neoadjuvant chemotherapy (NAC) and BC recurrence. We performed targeted ultra-deep sequencing of plasma DNAs, matched germline DNAs and tumor DNAs from locally advanced BC patients. Serial plasma DNAs were collected at diagnosis, after the 1(st) cycle of NAC and after curative surgery...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156792/liquid-biopsy-in-colon-cancer-comparison-of-different-circulating-dna-extraction-systems-following-absolute-quantification-of-kras-mutations-using-intplex-allele-specific-pcr
#19
Vera Kloten, Nadine Rüchel, Nadina Ortiz Brüchle, Janina Gasthaus, Nils Freudenmacher, Florian Steib, Jolein Mijnes, Julian Eschenbruch, Marcel Binnebösel, Ruth Knüchel, Edgar Dahl
Non-invasive molecular analysis of circulating tumor DNA (ctDNA) is a promising application in personalized cancer management, although there is still much to learn about the biological characteristics of ctDNA. The present study compared absolute amounts of KRAS mutated ctDNA and total circulating cell-free DNA (cfDNA) in colorectal cancer (CRC) patients (n=50) from various stages and healthy controls (n=8) by Intplex allele-specific and digital droplet PCR. In addition, the impact of two prominent extraction techniques (silica-based membrane vs...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137972/circulating-tumoral-dna-preanalytical-validation-and-quality-control-in-a-diagnostic-laboratory
#20
Sergey Nikolaev, Laure Lemmens, Thibaud Koessler, Jean-Louis Blouin, Thierry Nouspikel
We present the results of our technical validation process in establishing the analysis of circulating tumor DNA (ctDNA) as a diagnostic tool. Like most cells in our body, tumor cells shed DNA in the blood flow. Analysis of ctDNA mutational content can provide invaluable information on the genetic makeup of a tumor, and assist oncologists in deciding on therapy, or in following residual disease. However, low absolute amounts of circulating DNA and low tumor fraction constitute formidable analytical challenges...
November 11, 2017: Analytical Biochemistry
keyword
keyword
34533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"